Why Are Corticosteroids Not Routinely Used to Treat AIDP?

It is completely logical to assume that an “inflammatory” condition like Acute Inflammatory Demyelinating Polyradiculoneuropathy (AIDP) should be treated with anti-inflammatory corticosteroids (like prednisone or intravenous methylprednisolone). However, clinical trials have not demonstrated a clinically meaningful benefit from corticosteroids for classic AIDP ^[1]. Because steroids do not significantly speed up recovery and carry the risk of side effects, major medical guidelines advise against their routine use ^[2].

Urgent Safety Warning: AIDP can progress rapidly. If you experience new or worsening shortness of breath, difficulty swallowing, choking, inability to handle saliva, a weak cough, changes in your voice, or rapidly worsening weakness, seek emergency medical care immediately. Do not wait for a routine appointment.

What the Evidence Shows About Steroids

While corticosteroids are a cornerstone treatment for many autoimmune diseases, AIDP involves a complex immune response. Although immune and inflammatory mechanisms are involved, clinical trials have not shown that corticosteroids improve outcomes; the exact biological reasons why they do not work for AIDP are not fully understood ^[3].

Over the years, researchers have conducted rigorous clinical trials to see if either oral or intravenous steroids could help patients recover faster. A comprehensive review of these trials found that:

• No improvement in recovery speed: Intravenous steroids did not significantly improve patients’ disability levels at four weeks ^[1]. Oral steroids were associated with less improvement at four weeks, though this was based on very low-quality evidence ^[1].
• No long-term benefit: At one year, patients treated with steroids were no more likely to be walking independently than those who did not receive them ^[1].
• Risk of complications: Patients receiving steroids had a significantly higher risk of developing short-term complications, such as hyperglycemia (high blood sugar) requiring insulin ^[1].

Because of this evidence, the European Academy of Neurology and Peripheral Nerve Society (EAN/PNS) guidelines formally recommend against the use of oral corticosteroids and weakly recommend against intravenous corticosteroids for treating classic GBS/AIDP ^[2].

(Note: If you are already taking corticosteroids for a different medical condition, do not stop taking them abruptly without speaking to your doctor. Furthermore, steroids may be appropriate if your diagnosis is revised to a different condition, such as chronic inflammatory demyelinating polyneuropathy (CIDP) ^[4].)

The Recommended Treatments: IVIG and PLEX

Instead of steroids, the standard of care involves two disease-modifying treatments. While neither treatment provides an instantaneous cure or immediately repairs damaged nerves, they can help stop the disease from progressing and shorten recovery time:

• Intravenous Immunoglobulin (IVIG): This treatment delivers donor immunoglobulins (antibodies) into your bloodstream to help modulate and calm your immune system’s attack on your nerves ^[5][6].
• Plasma Exchange (PLEX): Also known as plasmapheresis, this procedure filters your blood to remove plasma constituents—including the harmful antibodies and immune proteins—before replacing the plasma and returning the blood to your body ^[5][6].

Clinical guidelines recommend starting these treatments promptly if you are unable to walk unaided. Generally, IVIG is recommended within the first two weeks of weakness onset (and may be considered up to four weeks), while PLEX is recommended within the first four weeks ^[2]. Treatment may also be considered earlier if symptoms are rapidly worsening or affecting your breathing.

IVIG and PLEX are generally considered to have similar efficacy ^[7]. Your care team will choose the best option based on your specific medical history, kidney function, clotting risks, and vascular access.

If your care team has not prescribed steroids, it is not because they are ignoring the inflammation. It is because they are following the best available evidence to provide treatments that actually work for AIDP while avoiding medications that could cause unnecessary harm.